Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe Sells 11,546 Shares

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 11,546 shares of the company’s stock in a transaction on Tuesday, June 25th. The shares were sold at an average price of $22.21, for a total transaction of $256,436.66. Following the sale, the chief financial officer now owns 177,449 shares of the company’s stock, valued at $3,941,142.29. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Oluyemi Okupe also recently made the following trade(s):

• On Thursday, June 6th, Oluyemi Okupe sold 98,635 shares of Hims & Hers Health stock. The shares were sold at an average price of $21.42, for a total transaction of $2,112,761.70.

Hims & Hers Health Price Performance

Shares of Hims & Hers Health stock opened at $21.56 on Thursday. The firm has a market cap of $4.63 billion, a price-to-earnings ratio of -2,156.00 and a beta of 1.08. Hims & Hers Health, Inc. has a 1 year low of $5.65 and a 1 year high of $25.74. The company has a 50-day moving average of $17.27 and a 200 day moving average of $13.36.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings data on Monday, May 6th. The company reported $0.05 earnings per share for the quarter, beating analysts’ consensus estimates of $0.02 by $0.03. The business had revenue of $278.20 million during the quarter, compared to analyst estimates of $270.37 million. Hims & Hers Health had a negative net margin of 0.24% and a negative return on equity of 0.70%. Hims & Hers Health’s revenue was up 45.8% compared to the same quarter last year. During the same period last year, the business earned ($0.05) EPS. On average, equities analysts anticipate that Hims & Hers Health, Inc. will post 0.19 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on HIMS. Piper Sandler boosted their price objective on shares of Hims & Hers Health from $11.00 to $13.00 and gave the company a “neutral” rating in a research report on Tuesday, May 7th. Imperial Capital raised shares of Hims & Hers Health from an “in-line” rating to an “outperform” rating and set a $16.00 price objective on the stock in a research report on Wednesday, February 28th. Seaport Res Ptn reissued a “buy” rating on shares of Hims & Hers Health in a research report on Friday, April 26th. Canaccord Genuity Group boosted their price objective on shares of Hims & Hers Health from $20.00 to $24.00 and gave the company a “buy” rating in a research report on Wednesday, May 22nd. Finally, Bank of America boosted their price objective on shares of Hims & Hers Health from $22.00 to $26.00 and gave the company a “buy” rating in a research report on Thursday, June 13th. Seven investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $16.43.

Institutional Trading of Hims & Hers Health

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Belpointe Asset Management LLC increased its stake in Hims & Hers Health by 10.0% during the 4th quarter. Belpointe Asset Management LLC now owns 13,238 shares of the company’s stock valued at $118,000 after purchasing an additional 1,205 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Hims & Hers Health by 5.6% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 29,335 shares of the company’s stock valued at $261,000 after purchasing an additional 1,561 shares in the last quarter. Swiss National Bank increased its stake in Hims & Hers Health by 0.7% during the 1st quarter. Swiss National Bank now owns 281,500 shares of the company’s stock valued at $4,355,000 after purchasing an additional 2,000 shares in the last quarter. ProShare Advisors LLC increased its stake in Hims & Hers Health by 10.0% during the 1st quarter. ProShare Advisors LLC now owns 22,257 shares of the company’s stock valued at $344,000 after purchasing an additional 2,023 shares in the last quarter. Finally, Principal Financial Group Inc. boosted its holdings in shares of Hims & Hers Health by 17.9% during the 1st quarter. Principal Financial Group Inc. now owns 16,655 shares of the company’s stock valued at $258,000 after acquiring an additional 2,525 shares during the last quarter. 63.52% of the stock is currently owned by institutional investors.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.